|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.26 USD | +3.26% |
|
-4.39% | +8.77% |
Company Valuation: Cytokinetics, Incorporated
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,823 | 4,336 | 8,186 | 5,551 | 7,769 | 9,106 | - | - |
| Change | - | 13.41% | 88.8% | -32.19% | 39.94% | 17.22% | - | - |
| Enterprise Value (EV) 1 | 3,495 | 4,163 | 8,179 | 5,144 | 7,740 | 8,523 | 8,506 | 7,771 |
| Change | - | 19.13% | 96.47% | -37.11% | 50.47% | 10.12% | -0.2% | -8.64% |
| P/E Ratio | -16.3x | -10.6x | -15.3x | -8.94x | -9.72x | -10.4x | -14.4x | -33.5x |
| PBR | 15.8x | -40.3x | -22x | -41.1x | -11.8x | -43x | -129x | 14.4x |
| PEG | - | -0.2x | -0.6x | 2.56x | -0.4x | 8.96x | 0.5x | 0.6x |
| Capitalization / Revenue | 54.3x | 45.8x | 1,087x | 300x | 88.2x | 83.3x | 23.5x | 10.7x |
| EV / Revenue | 49.6x | 44x | 1,086x | 278x | 87.9x | 78x | 22x | 9.17x |
| EV / EBITDA | -19x | -13.1x | -16.9x | -9.77x | -12.9x | -11.6x | -15.6x | -23.1x |
| EV / EBIT | -18.8x | -12.8x | -16.5x | -9.59x | -12.6x | -11.3x | -14.8x | -35.8x |
| EV / FCF | -18.3x | -13.4x | -19.7x | -12.9x | -14.5x | -12.9x | -15.4x | -30.3x |
| FCF Yield | -5.48% | -7.47% | -5.08% | -7.77% | -6.91% | -7.76% | -6.5% | -3.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.8 | -4.33 | -5.45 | -5.26 | -6.54 | -6.464 | -4.654 | -1.999 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 70.43 | 94.59 | 7.53 | 18.47 | 88.04 | 109.3 | 387.4 | 847.4 |
| EBITDA 1 | -184 | -318.4 | -484.3 | -526.7 | -602.1 | -732.4 | -544.6 | -336 |
| EBIT 1 | -186.3 | -324.2 | -496.2 | -536.2 | -612.3 | -752.4 | -573.7 | -217.2 |
| Net income 1 | -215.3 | -389 | -526.2 | -589.5 | -785 | -806 | -652.8 | -319.1 |
| Net Debt 1 | -328.8 | -173 | -7.451 | -407.6 | -29.01 | -583.5 | -600.6 | -1,335 |
| Reference price 2 | 45.58 | 45.82 | 83.49 | 47.04 | 63.54 | 67.07 | 67.07 | 67.07 |
| Nbr of stocks (in thousands) | 83,883 | 94,631 | 98,054 | 118,014 | 122,265 | 135,771 | - | - |
| Announcement Date | 24/02/22 | 01/03/23 | 27/02/24 | 27/02/25 | 24/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.38x | 78x | -11.64x | -.--% | 9.11B | |
| 32.3x | 8.39x | 25.37x | 0.06% | 54.82B | |
| 16.24x | 4.87x | 10.58x | 1.85% | 43.27B | |
| -16.97x | 3.74x | -6.55x | -.--% | 21.79B | |
| -34.28x | 11.45x | -33.43x | -.--% | 19.92B | |
| 19.37x | 3.76x | 9.77x | -.--% | 15.67B | |
| 21.29x | 4.28x | 14.15x | -.--% | 15.26B | |
| 16.63x | 4.79x | 11.24x | -.--% | 13.22B | |
| 38.34x | 14.76x | 43.34x | 0.17% | 11.58B | |
| -419.07x | 28.52x | -3179.37x | -.--% | 11.94B | |
| Average | -33.65x | 16.26x | -311.65x | 0.21% | 21.66B | |
| Weighted average by Cap. | -11.02x | 11.03x | -166.33x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CYTK Stock
- Valuation Cytokinetics, Incorporated
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition